tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2021 Jan 28;137:111300.
doi: 10.1016/j.biopha.2021.111300. Online ahead of print.
Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
Saniya Mahendiratta[SUP] 1 [/SUP], Seema Bansal[SUP] 2 [/SUP], Phulen Sarma[SUP] 3 [/SUP], Harish Kumar[SUP] 4 [/SUP], Gajendra Choudhary[SUP] 5 [/SUP], Subodh Kumar[SUP] 6 [/SUP], Ajay Prakash[SUP] 7 [/SUP], Rakesh Sehgal[SUP] 8 [/SUP], Bikash Medhi[SUP] 9 [/SUP]
Affiliations
Abstract
Background: SARS-CoV-2, which majorly affects the lungs and respiratory tract is thought due to dysregulation of the immune system which causes an immense imbalance of the cytokines. However, till now no standard treatment has been developed in treating the disease. On the other hand, it becomes important to prevent the acute respiratory tract infection due to COVID-19 which is the most dangerous phase leading to increased mortality. Hence this systematic review has been framed by pooling the available data of the use of stem cells in SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS.
Methods: 6 literature databases (PubMed, EMBASE, Scopus, Google Scholar, Clinicaltrials.gov, and Clinical trial registry of India) were searched for relevant studies till 10th August 2020 using keywords stem cells, mesenchymal stem cells, cell therapy, SARS CoV-2, SARS Coronavirus, Coronavirus 2, COVID-19, nCoV-19, Novel Coronavirus, MERS CoV, ARDS, acute respiratory distress syndrome.
Results: The observations of this systematic review suggest capability of MSCs in reducing the systemic inflammation and protecting against SARS-CoV-2 as evidenced by the available clinical data.
Conclusion: MSCs can overcome the clinical challenges currently faced by SARS-CoV-2 infected patients, specifically who are seriously ill and not responding to conventional therapies. Though the available clinical data is motivating, still predicting the therapeutic potential of MSCs will be too early in COVID-19. Hence, further studies in a larger cohort of patients becomes a prerequisite to validate their potential efficacy.
Keywords: ARDS; Coronavirus; Immunomodulatory; SARS-CoV-2; Stem cell therapy.
. 2021 Jan 28;137:111300.
doi: 10.1016/j.biopha.2021.111300. Online ahead of print.
Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
Saniya Mahendiratta[SUP] 1 [/SUP], Seema Bansal[SUP] 2 [/SUP], Phulen Sarma[SUP] 3 [/SUP], Harish Kumar[SUP] 4 [/SUP], Gajendra Choudhary[SUP] 5 [/SUP], Subodh Kumar[SUP] 6 [/SUP], Ajay Prakash[SUP] 7 [/SUP], Rakesh Sehgal[SUP] 8 [/SUP], Bikash Medhi[SUP] 9 [/SUP]
Affiliations
- PMID: 33529945
- DOI: 10.1016/j.biopha.2021.111300
Abstract
Background: SARS-CoV-2, which majorly affects the lungs and respiratory tract is thought due to dysregulation of the immune system which causes an immense imbalance of the cytokines. However, till now no standard treatment has been developed in treating the disease. On the other hand, it becomes important to prevent the acute respiratory tract infection due to COVID-19 which is the most dangerous phase leading to increased mortality. Hence this systematic review has been framed by pooling the available data of the use of stem cells in SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS.
Methods: 6 literature databases (PubMed, EMBASE, Scopus, Google Scholar, Clinicaltrials.gov, and Clinical trial registry of India) were searched for relevant studies till 10th August 2020 using keywords stem cells, mesenchymal stem cells, cell therapy, SARS CoV-2, SARS Coronavirus, Coronavirus 2, COVID-19, nCoV-19, Novel Coronavirus, MERS CoV, ARDS, acute respiratory distress syndrome.
Results: The observations of this systematic review suggest capability of MSCs in reducing the systemic inflammation and protecting against SARS-CoV-2 as evidenced by the available clinical data.
Conclusion: MSCs can overcome the clinical challenges currently faced by SARS-CoV-2 infected patients, specifically who are seriously ill and not responding to conventional therapies. Though the available clinical data is motivating, still predicting the therapeutic potential of MSCs will be too early in COVID-19. Hence, further studies in a larger cohort of patients becomes a prerequisite to validate their potential efficacy.
Keywords: ARDS; Coronavirus; Immunomodulatory; SARS-CoV-2; Stem cell therapy.